7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 19, 2016 -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that the company has been selected to the 2016 Gator100.
The Gator100, named after the University of Florida’s mascot, annually recognizes and celebrates the 100 fastest-growing businesses in the world that are either owned or led by University of Florida graduates. It is sponsored by the University‘s Entrepreneurship & Innovation Center and Warrington College of Business. The winning companies were announced earlier today at the Gator100 Awards Gala at the University of Florida.
“On behalf of AGTC, I would like to thank everyone at the University of Florida who has been instrumental in the growth of our company,” said Sue Washer, President and CEO of AGTC. “Many groups within UF including the Sid Martin Biotechnology Incubator, Office of Technology Licensing, Entrepreneurship & Innovation Center, College of Medicine and the Powell Gene Therapy Center have provided ongoing support as we have evolved from a small startup to publicly traded company.”
AGTC has a long-standing relationship with the University of Florida, where a significant portion of the company’s technology was developed. AGTC maintains extensive ties to the University through multiple Sponsored Research Agreements, covering basic research projects that will enhance its basic AAV technology platform and support of pre-clinical and clinical development for new product candidates. During its early years, AGTC was located within the University’s Sid Martin Biotechnology Incubator.
Ms. Washer is a graduate of the University of Florida’s Warrington College of Business. In addition, all five of AGTC’s Scientific Founders, including William W. Hauswirth, a member of the company’s scientific advisory board, have been or are professors at the University of Florida College of Medicine.
“We congratulate AGTC for being named to the Gator100, and applaud the company’s recent achievements,” said Jamie Kraft, Director of the Entrepreneurship & Innovation Center at the Warrington College of Business. “Biotechnology is an important industry impacting Florida’s growing life sciences hub, and AGTC has proven itself as an emerging leader in the promising field of gene therapy. We are confident that the company will continue to make meaningful progress in developing novel therapies to treat rare diseases with significant unmet needs and look forward to our continued collaboration.”
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates focus on inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.
AGTC’s product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis, X-linked retinitis pigmentosa, achromatopsia, wet age-related macular degeneration and blue cone monochromacy), non-ophthalmology programs in alpha-1 antitrypsin deficiency and adrenoleukodystrophy and proof-of-concept data in multiple additional indications. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.
IR/PR CONTACTS: David Carey (IR) or Danielle Lewis (PR) Lazar Partners Ltd. T: (212) 867-1768 or (212) 843-0211 [email protected] or [email protected] Corporate Contacts: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 [email protected] Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected]
